Facebook The Dorzagliatin Breakthrough: A 27% CAGR Trajectory to US$2.1 Billion in First-in-Class Type 2 Diabetes Therapy
Logo

The Dorzagliatin Breakthrough: A 27% CAGR Trajectory to US$2.1 Billion in First-in-Class Type 2 Diabetes Therapy

クレジット
Avatar
Illustrator
The Dorzagliatin Breakthrough: A 27% CAGR Trajectory to US$2.1 Billion in First-in-Class Type 2 Diabetes Therapy-1
シェア
zozo linの他の作品